Abstract | BACKGROUND: METHODS: A total of 381 NSCLC patients with Tumor, Node, Metastasis (TNM) stage I-IIIA who underwent tumor resection were retrospectively screened. Immunohistochemistry staining and semi-quantitative scoring were used to evaluate CCT6A expression in tumor and adjacent tissues. Clinicopathological features were retrieved. Disease-free survival (DFS) and overall survival (OS) were calculated. RESULTS: CCT6A expression was elevated in tumor tissue (CCT6A high 47.5% vs. low 52.5%) compared with adjacent tissue (CCT6A high 30.4% vs. low 69.6%) (P < 0.001), and ROC curve displayed that CCT6A could distinguish tumor tissue from adjacent tissue. Moreover, tumor CCT6A high expression was associated with lymph node metastasis (P = 0.001), elevated TNM stage (P = 0.002), and abnormal carcinoembryonic antigen (P = 0.022). Kaplan-Meier curves displayed that tumor CCT6A high expression was negatively correlated with DFS and OS (all P < 0.001). Cox's regression analysis disclosed that tumor CCT6A high expression independently predicted worse DFS (P < 0.001) (hazard ratio (HR) 1.659 (95% confidence interval (CI) 1.318-2.089)), and OS (P < 0.001) (HR 1.779 (95%CI 1.378-2.298)). CONCLUSIONS: CCT6A may present some clinical value in the management of NSCLC.
|
Authors | Ting Zhang, Wang Shi, Ke Tian, Yushan Kong |
Journal | World journal of surgical oncology
(World J Surg Oncol)
Vol. 18
Issue 1
Pg. 156
(Jul 06 2020)
ISSN: 1477-7819 [Electronic] England |
PMID | 32631353
(Publication Type: Journal Article)
|
Chemical References |
- CCT6A protein, human
- Carcinoembryonic Antigen
- Chaperonin Containing TCP-1
|
Topics |
- Carcinoembryonic Antigen
- Carcinoma, Non-Small-Cell Lung
- Chaperonin Containing TCP-1
- Humans
- Lung Neoplasms
- Lymphatic Metastasis
- Prognosis
- Retrospective Studies
|